← Back to Clinical Trials
Recruiting NCT06898320
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Trial Parameters
Condition Heart Injuries
Sponsor IRCCS Burlo Garofolo
Study Type OBSERVATIONAL
Phase N/A
Enrollment 22
Sex ALL
Min Age 0 Years
Max Age 18 Years
Start Date 2023-07-21
Completion 2033-07-21
All Conditions
Brief Summary
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
Eligibility Criteria
Inclusion Criteria: * Paediatric oncological patients 0-18 years * Planned start of anthracycline therapy * Normal left ventricular systolic function according to International Guidelines before the treatment with AC Exclusion Criteria: * Previous anthracycline treatment, bone marrow transplantation or chest radiation * Pre-anthracycline treatment echocardiographic evidence of: * More than mild pericardial effusion * More than mild mitral regurgitation * Poor echocardiographic acoustic window